An update to the American Radium Society's appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors

Radiother Oncol. 2025 Jan:202:110640. doi: 10.1016/j.radonc.2024.110640. Epub 2024 Nov 16.

Abstract

The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2 oligodendroglioma or astrocytoma, any grade 3 oligodendroglioma or astrocytoma, or combined with radiotherapy and/or chemotherapy for any grade 2-3 glioma.

Keywords: Astrocytoma; Grade 2 glioma; IDH inhibitor; Oligodendroglioma; Vorasidenib.

MeSH terms

  • Brain Neoplasms* / drug therapy
  • Brain Neoplasms* / pathology
  • Glioma* / drug therapy
  • Glioma* / pathology
  • Humans
  • Isocitrate Dehydrogenase* / antagonists & inhibitors
  • Isocitrate Dehydrogenase* / genetics
  • Neoplasm Grading
  • Practice Guidelines as Topic
  • Societies, Medical
  • United States

Substances

  • Isocitrate Dehydrogenase